Premium
Bcl‐2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide
Author(s) -
Zhang Y.,
Shen W.L.
Publication year - 2003
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1016/s1065-6995(03)00164-1
Subject(s) - arsenic trioxide , arsenic , flow cytometry , apoptosis , chemistry , k562 cells , trioxide , leukemia , cancer research , cell culture , microbiology and biotechnology , biology , biochemistry , immunology , organic chemistry , genetics , sulfur
Cell culture, tissue chemistry and flow cytometry were used to determine whether antisense bcl‐2 oligodeoxynucleotides enhanced the sensitivity of leukemia cells to arsenic trioxide. A combination of arsenic trioxide with antisense bcl‐2 oligodeoxynucleotides inhibited cell growth, induced apoptosis and induced bcl‐2 protein expression in K562 and NB4 leukemic cells more significantly than either arsenic trioxide or the oligodeoxynucleotides on their own ( P <0.01). Thus, bcl‐2 antisense oligodeoxynucleotides increase the sensitivity of leukemic cells to arsenic trioxide. Combined use of the two agents could be a novel and attractive strategy in leukemia treatment.